Page last updated: 2024-11-08

ma-1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tipiracil: inhibits thymidine phosphorylase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tipiracil : A member of the class of pyrimidones that is uracil substituted by chloro and (2-iminopyrrolidin-1-yl)methyl groups at positions 5 and 6 respectively. Used (as the hydrochloride salt) in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6323266
CHEMBL ID235668
CHEBI ID90879
SCHEMBL ID1682960
MeSH IDM0093031

Synonyms (48)

Synonym
TPI ,
DB02631
5-chloro-6-{[(2e)-2-imino-1-pyrrolidinyl]methyl}-2,4(1h,3h)-pyrimidinedione
5-chloro-6-(1-(2-iminopyrrolidinyl) methyl) uracil
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4(1h,3h)-dione
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
bdbm20079
tpi (freebase)
tipiracil
CHEMBL235668
ma-1
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1h-pyrimidine-2,4-dione
unii-ngo10k751p
5-chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4-(1h,3h)-dione
5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1h,3h)-pyrimidinedione
ngo10k751p ,
183204-74-2
5-cimu
tipiracil [usan:inn]
tipiracil [inn]
tipiracil [who-dd]
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1h,3h)-dione
tipiracil [mi]
tipiracil [usan]
CHEBI:90879
CS-5895
HY-A0063A
SCHEMBL1682960
gtpl8696
DB09343
AKOS027324917
5-chloro-6-{[(2z)-2-iminopyrrolidin-1-yl]methyl}pyrimidine-2,4(1h,3h)-dione
'5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4(1h,3h)-dione'
BCP24231
Q27458871
FT-0758894
5-chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1h,3h)-dione
Q21098889
NCGC00389632-07
HMS3745A05
NCGC00389632-02
F85441
MS-23436
bdbm50531739
EN300-23231135
A927069
5-chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1h,3h)-dione,
DTXSID601025833

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Major adverse events were neutropenia, leukopenia, anemia, and nausea."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
"5% of patients (n = 101), 253 adverse events (AE) were documented, most of them drug-related (n = 135)."( Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Fuchs, M; Karthaus, M; Kasper, S; Kisro, J; Müller, C; Rafiyan, MR; Schulz-Abelius, A; Stein, A, 2018
)
0.48
" Among FTD/TPI-treated patients, grade 3 or higher adverse events of any cause occurred in 122 of 145 patients (84."( Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E, 2020
)
0.56
" Adverse events (AEs) were experienced by 96."( Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Atlan, D; Bachet, JB; Becquart, M; Cicin, I; Cremolini, C; Falcone, A; Mounedji, N; Ozet, A; Phelip, JM; Portales, F; Price, T; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L, 2020
)
0.56
" Although the incidence of hematological toxicity in the elderly patient group was higher than that in the younger patient group, there were no significant differences in the rate of treatment discontinuation due to adverse events between the two groups."( The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
En, W; Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Ohira, M; Okazaki, Y; Shibutani, M, 2021
)
0.62
" Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]."( Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A, 2022
)
0.72
" The most frequent treatment-emergent adverse events were neutropenia (27."( Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
Ettrich, TJ; Heinemann, V; Hess, J; Karthaus, M; Klein, A; Kretzschmar, A; Pelz, H; Reisländer, T; Riera-Knorrenschild, J; Vehling-Kaiser, U; Weiss, L; Welslau, M, 2022
)
0.72
" Adverse events of any grade were reported in 58% of patients."( Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T, 2022
)
0.72
" The primary endpoints were dose-limiting toxicities (DLTs) in Cycle 1 as well as serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) throughout the study; secondary endpoints were pharmacodynamics parameters, objective tumor response, and urinary pharmacodynamics markers of target inhibition."( Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E, 2023
)
0.91
" Drug-related grade ≥ 3 adverse events included neutropenia (38."( Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.
Bachet, JB; Chevallier, B; Price, T; Taieb, J; Vidot, L; Wyrwicz, L, 2023
)
0.91
" Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13."( Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023
)
0.91
" In the overall population, the most common grade 3 or higher treatment-related adverse events were neutropenia (37%), anemia (32%) leukopenia (20%), thrombocytopenia (8%), and anorexia (7%)."( Safety and Efficacy of Trifluridine/Tipiracil Administered After Anti-PD-1 Therapies for Advanced Gastric Cancer.
Demachi, K; Kawazoe, A; Kotani, D; Nakamura, H; Okunaka, M; Shitara, K,
)
0.13
" No unexpected adverse events were observed in both groups."( Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Patients were given single doses of TAS-102 (35 mg/m(2) ) in the pharmacokinetic phase and received twice-daily doses of TAS-102 in 28-day cycles in the repeated administration phase for evaluating efficacy and safety."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" The favorable safety profile of trifluridine/tipiracil renders it a suitable option to be combined with other local therapies for metastatic lesions."( Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Lin, BR; Lin, YL; Liu, KL, 2020
)
0.56
"The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
0.72
"Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line for mCRC patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
0.72
" A Phase 1, 2-part (dose escalation, dose expansion), non-randomized, open-label, first-in-human study of CA102N, as monotherapy and in combination with trifluridine-tipiracil, was conducted in patients with locally advanced or metastatic solid tumors."( Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E, 2023
)
0.91
"From October 2020 to February 2022, patients with metastatic colorectal cancer who failed from 2 or more lines of prior therapy and treated with TAS-102 monotherapy, in combination with bevacizumab or immune checkpoint inhibitors (ICIs) were analyzed."( An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" Maximum concentrations of both drugs decreased by approximately 40%, indicating that food influenced the absorption and bioavailability of trifluridine and tipiracil hydrochloride, respectively."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
" It is a combination of two active pharmaceutical compounds, trifluridine, an antineoplastic thymidine-based nucleoside analog, and tipiracil, which enhances the bioavailability of trifluridine in vivo."( Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Matsuoka, K; Nakagawa, F; Suzuki, N; Takechi, T, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
"8%) had dosing modifications because of adverse events vs 101 (53."( Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E, 2020
)
0.56
"In this phase Ib study MODURATE, we optimized the dosing schedule and tested the efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure."( Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 2.4.2.4 (thymidine phosphorylase) inhibitorAn EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of thymidine phosphorylase (EC 2.4.2.4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
carboxamidineCompounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
pyrrolidinesAny of a class of heterocyclic amines having a saturated five-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine phosphorylaseEscherichia coli K-12Ki0.03500.03501.31173.1000AID465575
Thymidine phosphorylaseHomo sapiens (human)IC50 (µMol)0.03000.02001.58386.8000AID1623806; AID211058; AID211072
Thymidine phosphorylaseHomo sapiens (human)Ki0.00780.00130.27042.6000AID1623807; AID1797938; AID211073; AID211075; AID303486; AID303487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
DNA damage responseThymidine phosphorylaseEscherichia coli K-12
pyrimidine nucleobase metabolic processThymidine phosphorylaseEscherichia coli K-12
pyrimidine nucleoside metabolic processThymidine phosphorylaseEscherichia coli K-12
thymidine metabolic processThymidine phosphorylaseEscherichia coli K-12
mitochondrial genome maintenanceThymidine phosphorylaseHomo sapiens (human)
angiogenesisThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleobase metabolic processThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleoside metabolic processThymidine phosphorylaseHomo sapiens (human)
chemotaxisThymidine phosphorylaseHomo sapiens (human)
signal transductionThymidine phosphorylaseHomo sapiens (human)
cell differentiationThymidine phosphorylaseHomo sapiens (human)
regulation of myelinationThymidine phosphorylaseHomo sapiens (human)
dTMP catabolic processThymidine phosphorylaseHomo sapiens (human)
regulation of transmission of nerve impulseThymidine phosphorylaseHomo sapiens (human)
regulation of gastric motilityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseEscherichia coli K-12
thymidine phosphorylase activityThymidine phosphorylaseEscherichia coli K-12
glycosyltransferase activityThymidine phosphorylaseEscherichia coli K-12
pentosyltransferase activityThymidine phosphorylaseEscherichia coli K-12
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein bindingThymidine phosphorylaseHomo sapiens (human)
growth factor activityThymidine phosphorylaseHomo sapiens (human)
thymidine phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein homodimerization activityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytosolThymidine phosphorylaseEscherichia coli K-12
membraneThymidine phosphorylaseEscherichia coli K-12
cytosolThymidine phosphorylaseEscherichia coli K-12
cytosolThymidine phosphorylaseHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID303486Inhibition of human recombinant thymidine phosphorylase expressed in V79 cells2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase.
AID465575Inhibition of Escherichia coli thymidine phosphorylase2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
The role of phosphate in the action of thymidine phosphorylase inhibitors: Implications for the catalytic mechanism.
AID1623806Inhibition of thymidine phosphorylase (unknown origin)2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.
AID211058Inhibitory activity against Escherichia coli thymidine phosphorylase2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.
AID660982Inhibition of thymidine phosphorylase2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Fluorophosphonylated nucleoside derivatives as new series of thymidine phosphorylase multisubstrate inhibitors.
AID211072Inhibitory concentration against human thymidine phosphorylase TP2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Design of novel N-(2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model.
AID1623807Competitive inhibition of thymidine phosphorylase (unknown origin)2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.
AID211075Inhibitory activity against human thymidine phosphorylase2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.
AID211073Binding affinity towards recombinant thymidine phosphorylase TP2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Design of novel N-(2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model.
AID303487Inhibition of human placental thymidine phosphorylase2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1797938Enzyme Inhibition Assay from Article 10.1021/jm070644i: \\Discovery of 5-Substituted-6-chlorouracils as Efficient Inhibitors of Human Thymidine Phosphorylase.\\2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (2.61)29.6817
2010's22 (19.13)24.3611
2020's90 (78.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (26.72%)5.53%
Reviews6 (5.17%)6.00%
Case Studies7 (6.03%)4.05%
Observational8 (6.90%)0.25%
Other64 (55.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]